Systematic review highlights IL-23 inhibitors' safety and effectiveness in Crohn's disease, suggesting targeted treatments for best outcomes.
This is the first NMA comparing IL-23 inhibitors using contemporary evidence. The results offer practical insights for personalized CD treatment: guselkumab may be preferred for rapid response, mirikizumab for safety, and risankizumab for balanced efficacy.
No takes yet. Share an insight, caveat, or question.
Kaneko et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: